Aegerion Pharmaceuticals, Inc. 4
4 · Aegerion Pharmaceuticals, Inc. · Filed Dec 9, 2011
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2011-12-08$16.90/sh−2,472$41,765→ 2,621,401 total(indirect: See Footnote) - Sale
Common Stock
2011-12-09$16.89/sh−17,567$296,717→ 2,603,834 total(indirect: See Footnote)
Footnotes (1)
- [F1]These securities are indirectly beneficially owned in the following capacity: as General Partner of AHLS III GP Limited partnership which in turn is the General Partner of Advent Healthcare and Life Sciences III Limited Partnership and Advent Healthcare and Life Sciences III-A Limited Partnership.